Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2423874 | 1.00 | CYP2C19 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| SCHEMBL740140 | 1.00 | CYP2C19 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| Cadaverine Tartrate SCHEMBL18879377 | 0.90 | CYP2C19 (0.37) | CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29951019 | 0.88 | SLC6A2 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL25962718 | 0.85 | SLC6A2 (0.40) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| Hydrochloric Acid SCHEMBL28328339 | 0.84 | SLC6A2 (0.40) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| SCHEMBL28230632 | 0.81 | CYP2C19 (0.39) | CYP2C19SLC6A2SLC6A4SLC6A3MMP2 | |
| SCHEMBL21937953 | 0.80 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3MMP2MMP14 | |
| SCHEMBL10088963 | 0.79 | — | — | |
| SCHEMBL2890720 | 0.79 | POLB (0.41) | SLC6A2SLC6A4SLC6A3MMP2MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7390825-B1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265451-A1 | Process for the preparation of oxazolidinones and method of use thereof | OXA1L, OTC, ODC1 | CYP2C19 122/4885SLC6A2 4780/4885SLC6A4 4502/4885 |
| US-20080146458-A1 | PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF | OXA1L, OGFOD1, CYP51A1 | CYP2C19 7/4885SLC6A2 4748/4885SLC6A4 4595/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | CYP2C19 1331/4885SLC6A2 3902/4885SLC6A4 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.